167 related articles for article (PubMed ID: 36984543)
21. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
22. Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19.
Tsanovska H; Simova I; Genov V; Kundurzhiev T; Krasnaliev J; Kornovski V; Dimitrov N; Vekov T
Infect Disord Drug Targets; 2022; 22(6):e030322201650. PubMed ID: 35240966
[TBL] [Abstract][Full Text] [Related]
23. Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
Thoguluva Chandrasekar V; Venkatesalu B; Patel HK; Spadaccini M; Manteuffel J; Ramesh M
J Med Virol; 2021 Feb; 93(2):775-785. PubMed ID: 32667699
[TBL] [Abstract][Full Text] [Related]
24. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
25. Hydroxychloroquine in Treatment of Asymptomatic and Mildly Symptomatic COVID-19: A Multi-Centre Cohort Study.
Jain S; Sharma SK; Suri V; Yaddanapudi N; Malhotra P; Bhalla A; Singh MP; Koushal V; Kajal K; Jakulla RS; Marrapu S; Guru RR; Bora I; Chopra V; Sibia R; Puri GD
J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062802
[TBL] [Abstract][Full Text] [Related]
26. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
Klimke A; Hefner G; Will B; Voss U
Med Hypotheses; 2020 Sep; 142():109783. PubMed ID: 32402766
[TBL] [Abstract][Full Text] [Related]
27. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
29. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
[TBL] [Abstract][Full Text] [Related]
30. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.
Atefi N; Goodarzi A; Riahi T; Khodabandehloo N; Talebi Taher M; Najar Nobari N; Seirafianpour F; Mahdi Z; Baghestani A; Valizadeh R
Immun Inflamm Dis; 2023 Nov; 11(11):e1083. PubMed ID: 38018602
[TBL] [Abstract][Full Text] [Related]
32. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ
J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612
[TBL] [Abstract][Full Text] [Related]
33. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics.
Liu WD; Chang SY; Lan TY; Lin YC; Kao JH; Liao CH; Tsai MJ; Kuo PH; Huang YS; Wang JT; Sheng WH; Hsieh SC; Chiang BL; Chen YC; Chang SC
J Formos Med Assoc; 2021 May; 120(5):1269-1273. PubMed ID: 32888840
[TBL] [Abstract][Full Text] [Related]
34. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
[TBL] [Abstract][Full Text] [Related]
35. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
Lee JE; Lee SO; Heo J; Kim DW; Park MR; Son H; Kim D; Kim KH; Lee S; Lee SH
Antivir Ther; 2021; 26(1-2):34-42. PubMed ID: 35485345
[TBL] [Abstract][Full Text] [Related]
36. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
37. Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.
Saib A; Amara W; Wang P; Cattan S; Dellal A; Regaieg K; Nahon S; Nallet O; Nguyen LS
PLoS One; 2021; 16(6):e0252388. PubMed ID: 34106964
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19.
Shabani M; Totonchi M; Rezaeimirghaed O; Gachkar L; Hajiesmaeili M; Khoshkar A; Amirdosara M; Saffaei A; Shokouhi S; Mardani M; Alavi Darazam I; Karami A; Sharifi M; Zaman M; Abedheydari E; Sahraei Z
Pulm Pharmacol Ther; 2021 Oct; 70():102069. PubMed ID: 34389507
[TBL] [Abstract][Full Text] [Related]
39. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
[TBL] [Abstract][Full Text] [Related]
40. Hydroxychloroquine treatment in COVID-19: A descriptive observational analysis of 30 cases from a single center in Wuhan, China.
Xue H; Liu Y; Luo P; Liu X; Qiu L; Liu D; Li J
J Med Virol; 2020 Nov; 92(11):2523-2527. PubMed ID: 32779755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
